Printer Friendly

Learning from history or the rationale for considering surgical correction of vesicoureteral reflux.

Author(s): Jonathan Riddell, MD, FRCSC, Julie Franc-Guimond, MD, FRCSC

History reminds us of valuable lessons learned in the treatment of vesicoureteral reflux (VUR). Rates of reflux nephropathy (RN) have decreased remarkably over the past 50 years, owing in various degrees to more rapid detection of urinary tract infection (UTI) in infants and children, improved medical therapy and timely surgical intervention. Reflux nephropathy once accounted for 22% of all pediatric renal transplantations, and now accounts for less than 6%.[sup.1] Despite this improvement, 8.5% of chronic renal disease in North American children is still due to RN.[sup.2] In some series, there is a history of childhood pyelonephritis with subsequent renal scarring in up to 15% of adult renal transplantation.[sup.3] Therefore, the modern day debate on the optimal management of VUR has significant merit in terms of preventing RN, and its impact on pediatric and adult populations.

During the 1950s, Hutch was the first to suggest a link between VUR, pyelonephritis and renal scars based on his work on adult paraplegics, and the benefits of ureteral reimplantation.[sup.4] Politano, Leadbetter, Paquin and others improved upon the concept of an adequate length, detrusor-backed submucosal tunnel, cementing ureteral reimplant as a time-tested cornerstone in the management of VUR. 5,6 Reported contemporary success rates of antireflux surgery range from 96% to 98%.[sup.7]

The VUR treatment paradigm shifted from surgery towards medical management during the late 1970s. Lenaghan and colleagues showed a natural tendency for most VUR to resolve spontaneously. [sup.8] This work, coupled with the work of Smellie and colleagues,[sup.9,10] which showed a low rate of new scar formation on daily low dose antimicrobial prophylaxis, provided the rationale for the expectant VUR treatment we have seen for the past 3 decades. The rationale of preventing UTIs and pyelonephritis, while the refluxing kidney is at risk, formed the basis of the 1997 American Urological Association expert panel on VUR,[sup.11] where surgery is reserved for patients who failed on antibiotic prophylaxis and with high-grade reflux.

Issues with medical management

Several recent publications have questioned the efficacy of daily antimicrobial prophylaxis in terms of preventing UTI and new renal scarring (Table 1).[sup.12]-[sup.15] Breakthrough UTIs of up to 25% have been reported. This challenges the current assumption that daily antibiotic prophylaxis "prevents" UTIs, pyelonephritis and subsequent scar formation in affected renal units. Criticisms over the methodology of the aforementioned studies have led to great anticipation for the results of the Randomized lntervention for children with VesicoUreteral Reflux (RIVUR) study (Fig. 1).[sup.16]

Adequately designed and powered, this study will hopefully answer the question of whether prophylaxis prevents UTI and scarring in VUR patients (and thus potentially validate VUR management for the past 3 decades). Post-RIVUR, lingering concerns will still remain about antimicrobial prophylaxis. These include (1) increased bacterial resistance;[sup.17] (2) the inconvenience and risk associated with serial radiologic investigations; (3) decreased cost-effectiveness;[sup.18] (4) the clinical versus statistical significance of any result;[sup.19] and (5) the fate of those refluxers who do not resolve over time, in that we are shifting the progression of chronic renal disease into adulthood given the known, slow progression of reflux nephropathy.

Some proponents of medical therapy have proposed that early treatment of early pyelonephritis can decrease the risk or lessen scar formation.[sup.20] Two recent studies refute this idea. [sup.21,22] Hoberman and colleagues, in a large prospective trial of oral versus intravenous therapy for UTIs in young children, found no significant difference in scarring among children who presented after 24 hours of fever compared with those who presented sooner.[sup.21] Hewitt and colleagues used data from 2 multicentre, prospective, randomized controlled trials to demonstrate a 30.7% scar rate on dimercaptosuccinic acid (DMSA) 12 months after an acute pyelonephritis.[sup.22] Progressive delay in antibiotic treatment from <1 day to >5 days after onset of fever was not associated with increased scarring. In other words, prompt treatment of febrile UTI does not prevent associated scarring and/or the potential for RN.

Advances in surgical technique

While the debate over the efficacy of medical management continues, there must be an overt acknowledgement in any VUR debate that ureteral reimplantation cures reflux. With published minimal acceptable success rates of 95% and reproducible results reported as high as 99%, pediatric urologists have essentially perfected the art of the ureteral reimplant. At our institution, unilateral reimplantation is generally performed extravesically. Bilateral reimplantation is performed by an intravesical, cross-trigonal fashion to avoid the risk of transient postoperatively urinary retention observed with bilateral extravesical reimplantation (4% to 15%). Other reported complications of ureteral reimplantation include mild transient hydronephrosis in 6% to 7%, and an overall rate of ureteral obstruction requiring revision in <1%.

The perioperative management of the child undergoing ureteral reimplantation has changed dramatically. Two-week hospital stays in the early series have evolved into outpatient or overnight stays. Routine placement of suprapubic catheters, ureteral stents and surgical drains have been abandoned, and most patients with uncomplicated ureteral reimplants are discharged on postoperative day 1 with no tubes in place.

Pediatric anesthesia has also improved greatly. Judicious use of anti-inflammatories and anticholinergics decrease narcotic requirements and relieve bladder spasms. Regional blocks and/or continuous epidural infusions help children recover quickly by providing pre-emptive and better pain control; these are the standard at our centre.

Finally, as laparoscopic, vesicoscopic and robotic approaches gain acceptance as equivalent or superior in terms of success, morbidity from ureteral reimplantation will be further reduced.

Role of endoscopic bulking agents

Endoscopic bulking agents represent an extension of the surgical armamentarium. Originally pioneered over 30 years ago as an alternative to ureteral reimplantation,[sup.23] endoscopic injection for VUR has undergone several modifications of technique, and injection material (polytetrafluoroethylene, silicone paste, collagen, dextranomer/hyaluronic acid copolymer). Currently, dextranomer/hyaluronic acid copolymer is the dominant injectable in part due to its biocompatibility (both contents are biodegradeable polysaccharides) and lack of migration (due to infiltration with endogenous connective tissue). Controversy exists as to the exact mechanism by which reflux is prevented, and success rates are highly variable (60% to 90%). At our institution, endoscopic injection has evolved into a common surgical intervention performed for VUR, especially for lower grade reflux. As with any emerging technology, long-term, prospective studies are needed to better define short- and long-term success and complications and to further clarify the role of endoscopic injection in treating VUR.


From the original animal work of Ransley and Risdon,[sup.24] we know that reflux in and of itself is not a disease. Add, however, UTI to VUR, with the appropriate confluence of bacterial virulence and host factors, and renal scarring can ensue. Although the exact pathogenesis of renal scarring is not well-understood, the end result, reflux nephropathy, is understood, and could be entirely preventable.

Given that most reflux is self-limited, the key to any management strategy is selecting out the small minority of patients who are at risk for future deterioration. To avoid overtreatment, some authors are advocating a "top-down" approach to investigation of first febrile UTI.[sup.25] Rather than starting with voiding cystourethrography and identifying mainly "benign VUR," ultrasound and DMSA has become the first-line investigation. Recurrent UTI, and/or renal scars motivate cystography, which then contributes to stratification into low- and high-risk groups in terms of the potential for progressive renal damage. The presence of renal scars and reflux at initial presentation is associated with a 17-fold risk of progressive renal damage over the presence of reflux alone. Though we applaud the efforts to characterize at-risk populations, we do not condone an algorithm that waits for the disease process to become macroscopic before initiating therapy. Further prospective studies are necessary to better identify and characterize high-risk populations with VUR, as well as to validate surgical efficacy and other de novo strategies at preventing renal deterioration in these groups. A search at the molecular level for either a genetic or protein marker of susceptibility could be the eventual Rosetta stone for VUR management.

Until then, we believe every patient must be managed on a case-by-case basis. Multiple variables must be taken into account (Fig. 2).[sup.26] These variables can then be incorporated into evidence-based constructs, such as recently published nomograms,[sup.27] quantifying the likelihood of reflux resolution. A move from experience-based to evidenced-based medicine is essential in moving forward.


Until the role of antimicrobial prophylaxis is clarified, surgical intervention in the form of ureteral reimplantation remains the gold standard for the prevention of reflux nephropathy in susceptible renal units.

Competing Interests: None declared.

This paper has been peer-reviewed.


1. Cendron M. Reflux nephropathy. J Pediatr Urol 2008;4:414-21.

2. Novak TE, Mathews R, Martz K, et al. Progression of chronic kidney disease in children with vesicoureteral reflux: the North American Pediatric Renal Trials Collaborative Studies Database. J Urol 2009;1824Suppl:1678-81.

3. Coulthard MG. Vesicoureteric reflux is not a benign condition. Pediatr Nephrol 2009;24:227-32.

4. Hutch JA. Vesico-ureteral reflux in the paraplegic: cause and correction. J Urol 1952;68:457-69.

5. Politano VA, Leadbetter WF. An operative technique for the correction of vesicoureteral reflux. J Urol 1958;79:932-41.

6. Paquin AJ. Ureterovesical anastomosis: The description and evaluation of a technique. J Urol 1959;82:573.

7. Austin JC, Cooper CS. Vesicoureteral reflux: surgical approaches. Urol Clin N Am 2004;31:543-57.

8. Lenaghan D, Whitaker JG, Jensen F, et al. The natural history of reflux and long-term effects of reflux on the kidney. J Urol 1976;115:728-30.

9. Smellie JM, Normand IC. Bacteriuria, reflux, and renal scarring. Arch Dis Child 1975;50:581-5.

10. Smellie JM, Katz G, Gruneberg RN. Controlled trial of prophylactic treatment in childhood urinary tract infection. Lancet 1978;2:175-8.

11. Elder JS, Peters CA, Arant BS Jr, et al. Pediatric Vesicoureteral Reflux Guidelines Panel summary report on the management of primary vesicoureteral reflux in children. J Urol 1991;157:1846-51.

12. Conway PH, Cnaan A, Zaoutis T, et al. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA 2007;298:179-86.

13. Roussey-Kesler G, Gadjos V, Idres N, et al. Antibiotic prophylaxis for the prevention of recurrent urinary tract infection in children with low grade vesicoureteral reflux: results from a prospective randomized study. J Urol 2008;179:674-9.

14. Montini G, Rigon L, Zucchetta P, et al. Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. Pediatrics 2008;122:1064-71.

15. Garin EH, Olavarria F, Garcia Nieto V, et al. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 2006;117:626-32.

16. Mathews R, Carpenter M, Chesney R, et al. Controversies in the management of vesicoureteral reflux: the rationale for the RIVUR study. J Pediatr Urol 2009;5:336-41.

17. Chung A, Perera R, Brueggemann AB, et al. Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study. BMJ 2007;335:429.

18. Hsieh MH, Swana HS, Baskin LS, et al. Cost-utility analysis of treatment algorithms for moderate grade vesicoureteral reflux using Markov models. J Urol 2007;177:703-9; discussion 709.

19. Diaz M. Editorial comment. J Urol 2009;182:2445.

20. Coulthard MG, Verber I, Jani JC, et al. Can prompt treatment of childhood UTI prevent kidney scarring? Pediatr Nephrol 2009;24:2059-63.

21. Hoberman A, Wald ER, Hickey RW, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 1999;104:79-86.

22. Hewitt IK, Zucchetta P, Rigon L, et al. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian renal infection study trials. Pediatrics 2008;122:486-90.

23. Lackgren G, Kirsch AJ. Surgery Illustrated - Surgical Atlas Endoscopic treatment of vesicoureteral reflux. BJU Int 2010;105:1332-47.

24. Ransley PG, Risdon RA. Reflux and renal scarring. Br J Radiol 1978;14Suppl:1-35.

25. Merrick MV, Notghi A, Chalmers N, et al. Long term follow up to determine the prognostic value of imaging after urinary tract infection. Part 1: reflux. Arch Dis Child 1995;72:388-92.

26. Caldamone AA. Commentary to "Controversies in the management of vesicoureteral reflux - the rationale for the RIVUR study": Urinary tract infections and vesicoureteral reflux in childen: What have we learned? J Pediatr Urol 2009;5:342-3.

27. Estrada CR Jr, Passerotti CC, Graham DA, et al. Nomograms for predicting annual resolution rate of primary vesicoureteral reflux: results from 2,462 children. J Urol 2009;182:1535-41.


Table 1: Randomized lntervention for children with Vesico-Ureteral Reflux (RIVUR) study design (NIDDK-sponsored) [Table omitted]

Table 2: Vesicoureteral risk assessment [Table omitted]

Table 3: Recent publications addressing antimicrobial prophylaxis [Table omitted]

Author Affiliation(s):

[1] Universite de Montreal, CHU Sainte-Justine, Department of Surgery, Division of Pediatric Urology, Montreal, QC

Correspondence: Dr. Julie Franc-Guimond, Associate Professor, Universite de Montreal, CHU Sainte-Justine, Department of Surgery, Division of Pediatric Urology, A-4, 3175 Cote Sainte-Catherine, Montreal, QC H3T 1C5;
COPYRIGHT 2010 Canadian Urological Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Point/Counterpoint
Author:Riddell, Jonathan; Franc-Guimond, Julie
Publication:Canadian Urological Association Journal (CUAJ)
Article Type:Clinical report
Geographic Code:1CANA
Date:Aug 1, 2010
Previous Article:Rebuttal.
Next Article:Rebuttal.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |